MN/CA IX/G250 as a potential target for immunotherapy of renal cell carcinomas

[1]  M. Wei,et al.  Down-regulation of transmembrane carbonic anhydrases in renal cell carcinoma cell lines by wild-type von Hippel-Lindau transgenes. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[2]  J. Pastorek,et al.  Immunohistochemical study of colorectal tumors for expression of a novel transmembrane carbonic anhydrase, MN/CA IX, with potential value as a marker of cell proliferation. , 1998, The American journal of pathology.

[3]  J. Chmiel,et al.  Prostate specific antigen reverse transcriptase-polymerase chain reaction assay in preoperative staging of prostate cancer. , 1997, The Journal of urology.

[4]  E. Stanbridge,et al.  Identification of the MN/CA9 protein as a reliable diagnostic biomarker of clear cell carcinoma of the kidney. , 1997, Cancer research.

[5]  M. Stifelman,et al.  Expression of the tumor-associated gene MN: a potential biomarker for human renal cell carcinoma. , 1997, Cancer research.

[6]  R. Odze,et al.  MN antigen expression in normal, preneoplastic, and neoplastic esophagus: a clinicopathological study of a new cancer-associated biomarker. , 1997, Human pathology.

[7]  W. Oyen,et al.  Targeting of renal cell carcinoma with iodine-131-labeled chimeric monoclonal antibody G250. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  J. Pastorek,et al.  Carbonic anhydrase IX, MN/CA IX: analysis of stomach complementary DNA sequence and expression in human and rat alimentary tracts. , 1997, Gastroenterology.

[9]  P. Disaia,et al.  A study of biomarkers in cervical carcinoma and clinical correlation of the novel biomarker MN. , 1996, Gynecologic oncology.

[10]  R. Kettmann,et al.  Human MN/CA9 gene, a novel member of the carbonic anhydrase family: structure and exon to protein domain relationships. , 1996, Genomics.

[11]  F. Debruyne,et al.  Induction of tumor regression by passive transfer of antibody from mice vaccinated with anti-idiotype antibodies resembling a human renal cell carcinoma-associated antigen. , 1995, Urologic oncology.

[12]  R. Kettmann,et al.  Cloning and characterization of MN, a human tumor-associated protein with a domain homologous to carbonic anhydrase and a putative helix-loop-helix DNA binding segment. , 1994, Oncogene.

[13]  P. Disaia,et al.  Identification of the MN antigen as a diagnostic biomarker of cervical intraepithelial squamous and glandular neoplasia and cervical carcinomas. , 1994, The American journal of pathology.

[14]  F. Debruyne,et al.  Vaccination with ant‐idiotype antibodies mimicking a renal cell carcinoma‐associated antigen induces tumor immunity , 1994, International journal of cancer.

[15]  F. Debruyne,et al.  Internal image anti‐idiotype antibodies related to renal‐cell carcinoma‐associated antigen G250 , 1994, International journal of cancer.

[16]  S. Cascinu,et al.  Cisplatin, 5-fluorouracil and interferon alpha 2b for recurrent or metastatic head and neck cancer. , 1994, British Journal of Cancer.

[17]  G. Fleuren,et al.  Therapeutic effects of monoclonal antibody g250, interferons and tumor necrosis factor, in mice with renal‐cell carcinoma xenografts , 1994, International journal of cancer.

[18]  Wirth Mp.  Immunotherapy for metastatic renal cell carcinoma. , 1993 .

[19]  N. Bander,et al.  Antibody localization in human renal cell carcinoma: a phase I study of monoclonal antibody G250. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  R. Rees,et al.  Circulating prostate specific antigen-positive cells correlate with metastatic prostate cancer. , 1992, British journal of urology.

[21]  S. Pastoreková,et al.  A novel quasi-viral agent, MaTu, is a two-component system. , 1992, Virology.

[22]  Ritchie Aw,et al.  The natural history and clinical features of renal carcinoma. , 1987 .

[23]  G. Fleuren,et al.  Immunohistochemical analysis of monoclonal antibodies to renal antigens. Application in the diagnosis of renal cell carcinoma. , 1986, The American journal of pathology.

[24]  R. Figlin,et al.  Quantitative polymerase chain reaction does not improve preoperative prostate cancer staging: a clinicopathological molecular analysis of 121 patients. , 1996, The Journal of urology.

[25]  M. Wirth.  Immunotherapy for metastatic renal cell carcinoma. , 1993, The Urologic clinics of North America.

[26]  J. Dekernion,et al.  The natural history and clinical features of renal carcinoma. , 1987, Seminars in nephrology.